Literature DB >> 23954296

Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer.

Junji Itou1, Yoshiaki Matsumoto, Kiyotsugu Yoshikawa, Masakazu Toi.   

Abstract

In cell cultures, the dispersed phenotype is indicative of the migratory ability. Here we characterized Sal-like 4 (SALL4) as a dispersion factor in basal-like breast cancer. Our shRNA-mediated SALL4 knockdown system and SALL4 overexpression system revealed that SALL4 suppresses the expression of adhesion gene CDH1, and positively regulates the CDH1 suppressor ZEB1. Cell behavior analyses showed that SALL4 suppresses intercellular adhesion and maintains cell motility after cell-cell interaction and cell division, which results in the dispersed phenotype. Our findings indicate that SALL4 functions to suppress CDH1 expression and to maintain cell dispersion in basal-like breast cancer.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adhesion; Basal-like breast cancer; E-cadherin; EMT; Epithelial mesenchymal transition; HMLE; Migration; SALL4; Sal-like 4; Transcription factor; epithelial mesenchymal transition; immortalized human mammary epithelial cells

Mesh:

Substances:

Year:  2013        PMID: 23954296     DOI: 10.1016/j.febslet.2013.07.049

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21.

Authors:  Junji Itou; Wenzhao Li; Shinji Ito; Sunao Tanaka; Yoshiaki Matsumoto; Fumiaki Sato; Masakazu Toi
Journal:  J Biol Chem       Date:  2018-03-06       Impact factor: 5.157

Review 2.  SALL4, the missing link between stem cells, development and cancer.

Authors:  Hiro Tatetsu; Nikki R Kong; Gao Chong; Giovanni Amabile; Daniel G Tenen; Li Chai
Journal:  Gene       Date:  2016-02-16       Impact factor: 3.688

3.  Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.

Authors:  Bee Hui Liu; Chacko Jobichen; C S Brian Chia; Tim Hon Man Chan; Jing Ping Tang; Theodora X Y Chung; Jia Li; Anders Poulsen; Alvin W Hung; Xiaoying Koh-Stenta; Yaw Sing Tan; Chandra S Verma; Hong Kee Tan; Chan-Shuo Wu; Feng Li; Jeffrey Hill; Joma Joy; Henry Yang; Li Chai; J Sivaraman; Daniel G Tenen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-05       Impact factor: 11.205

Review 4.  Functional and clinical significance of SALL4 in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik
Journal:  Tumour Biol       Date:  2016-07-21

5.  An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer.

Authors:  Junji Itou; Sunao Tanaka; Fumiaki Sato; Ryutaro Akiyama; Yasuhiko Kawakami; Masakazu Toi
Journal:  Biochim Biophys Acta       Date:  2014-10-12

6.  The next new target in leukemia: The embryonic stem cell gene SALL4.

Authors:  Fei Wang; Wenxiu Zhao; Nikki Kong; Wei Cui; Li Chai
Journal:  Mol Cell Oncol       Date:  2014

7.  SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer.

Authors:  Lei Liu; Jing Zhang; Xiaoming Yang; Chi Fang; Huali Xu; Xiaowei Xi
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

8.  SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma.

Authors:  Gang Deng; Lei Zhu; Feizhou Huang; Wanpin Nie; Wei Huang; Hongbo Xu; Shaopeng Zheng; Zhongjie Yi; Tao Wan
Journal:  Oncotarget       Date:  2015-09-29

9.  Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.

Authors:  Su-xia Han; Jun-lan Wang; Xi-jing Guo; Chen-chen He; Xia Ying; Jin-lu Ma; Yuan-yuan Zhang; Qian Zhao; Qing Zhu
Journal:  J Immunol Res       Date:  2014-04-17       Impact factor: 4.818

10.  SALL4 promotes gastric cancer progression through activating CD44 expression.

Authors:  X Yuan; X Zhang; W Zhang; W Liang; P Zhang; H Shi; B Zhang; M Shao; Y Yan; H Qian; W Xu
Journal:  Oncogenesis       Date:  2016-11-07       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.